

## Seeking Drug Candidates to Address Transplant-related Complications

Asahi Kasei Pharma, a global pharmaceutical company, is seeking preclinical **drug candidates for specific transplant complications** with demonstrated *in vitro* efficacy, ideally supported by *in vivo* data.



### Approaches of Interest:

- **High priority indications** include transplant rejection, antibody-mediated rejection, delayed graft function, post-transplant lymphoproliferative disorder, transplant-associated thrombotic microangiopathy, chronic lung allograft dysfunction, cardiac allograft vasculopathy, whereas graft-versus-host disease is considered a lower priority
- Open to **biologics, small molecules, peptides** and **RNA-based approaches**
- Novel drug candidates that are intended for use in combination with existing drugs are within scope

### Out of Scope:

- Drug repurposing
- Cell therapy, probiotics, gene editing and AAV therapy
- Diagnostic products, medical devices, platform technologies, drug screening libraries
- Opportunities that focus solely on understanding mechanisms or exploring new targets

### Developmental Stages of Interest:

- Opportunities from preclinical research phase to late preclinical research stage are within scope, provided the efficacy has been confirmed in an *in vitro* study reflecting the treatment concept
- It is desirable that the effectiveness has been confirmed in an *in vivo* study using an animal model of a transplant related target indication

### Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. **Submissions must include details on both the indication and the stage of development of the opportunity. Please provide this information using this [submission form](#) . If not provided, we may request this information before your submission is accepted.** In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

## Opportunities sought

-  Spinout companies
-  Biotech assets
-  Research projects
-  Centres of excellence
-  Technologies
-  Academics and expertise

## Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **29th October 2025 - 11:59 pm GMT**

### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)